An interventional study of phenylephrine and isoproterenol in Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome and Tachycardia, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center — 2 open to participants now, 13 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · Vanderbilt University Medical Center.
Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2016, is one of 5 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 7th registered.
136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.
Browse Postural Orthostatic Tachycardia Syndrome studies →2 of the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is above the median of 36 across 102 interventional studies indexed under Postural Orthostatic Tachycardia Syndrome.
Median enrollment 40 across the 13 interventional studies, 70 across the 5 observational. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
5 of the studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT01988883Vanderbilt University Medical CenterModafinil and Cognitive Function in POTS | 2026-12 |
| NCT02725060Vanderbilt University Medical CenterAutoimmune Basis for Postural Tachycardia Syndrome | 2027-02 |
| NCT05375968Vanderbilt University Medical CenterSplanchnic Venous Capacitance in Postural Tachycardia Syndrome | 2027-05-31 |
| NCT03124355Vanderbilt University Medical CenterVagal Stimulation in POTS | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.
Postural tachycardia syndrome (POTS) is a debilitating disorder resulting from cardiovascular autonomic dysfunction, has many causes and is very difficult to treat effectively. The investigators have identified the presence of autoantibodies (immune proteins) directed against some receptors of the autonomic nervous system that can cause patient's symptoms on standing.
The present study is designed to test the hypothesis that patients with POTS harbor functional autoantibodies to adrenergic receptors that lead to an excessive tachycardia characteristic of POTS. For this purpose, this study will define the prevalence, burden, and the in vivo physiological significance of these adrenergic antibodies in a well-phenotyped and representative cohort of patients with POTS and a matched cohort of healthy control subjects, and will characterize the stability of these autoantibodies over time in affected POTS patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Healthy control subjects will be healthy, non-smoking and on no chronic medications at the time of the study. Healthy control subjects will be group-matched to the POTS patients for age and gender. We will attempt to study female patients in the first half of their menstrual cycle to minimize cyclical variability.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case: * Posture study with blood samples for autoantibody testing * 24-hour heart rhythm and blood pressure monitoring * autonomic function tests * Quantitative Axonal Sudomotor Reflex Testing * Total blood volume assessment * Pharmacologic testing with phenylephrine * Pharmacologic testing with isoproterenol * Cardiac output with rebreathing * Assessment of splanchnic capacitance * Microneurography
Drug: phenylephrine · Drug: isoproterenol · Radiation: 25 micro-Ci of radiation · Procedure: Posture study with blood samples · Procedure: 24-hour heart rhythm and blood pressure monitoring · Procedure: Quantitative Axonal Sudomotor Reflex Testing · Procedure: Autonomic function tests · Other: Rebreathing test · Other: Assessment of splanchnic capacitance · Procedure: microneurography
Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
Also known as: isuprel, isoprenaline
Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
Also known as: DAXOR
Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
Also known as: orthostatic challenge, orthostatic stress test
Blood pressure, heart rate and ECG monitoring for 24 hours
Also known as: 24 Holter
The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
Also known as: QSART, sweat test
The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
Cardiac output will be measured using the rebreathing technique (Innocor)
Also known as: cardiac output measurement
Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
microneurography will be measured in the peroneal nerve to assess sympathetic activity.
Also known as: msna
Autoantibody levels
Blood samples collected while supine during the posture study will be analyzed for autoantibody positivity in POTS patients and control subjects.
Time frame: up to 10 minutes
Blood pressure after phenylephrine boluses
Time frame: 1-2 minutes after bolus injections
Heart rate after isoproterenol boluses
Time frame: 1-2 minutes after bolus injections
Orthostatic change in heart rate
Difference between standing and supine heart rates.
Time frame: up to 10 minutes
Blood pressure response during phase IV of the Valsalva maneuver
Time frame: up to 10 minutes
Hear rate response during phase IV of the Valsalva maneuver
Time frame: up to 10 minutes
Started Feb 2016 (actual). Primary completion is estimated for Feb 2027, 132 months after the start.
Of 44 non-industry interventional studies with no phase under Postural Orthostatic Tachycardia Syndrome, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 132 months is above that.
Counting every sponsor, half of 44 studies reached it within 46 months; a quarter within 20 and three quarters within 61.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Feb 2027 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Phenylephrine · Isoproterenol
Postural Orthostatic Tachycardia Syndrome →
Vanderbilt University Medical Center →